Transplantation of Adult, Tissue-Specific RPE Stem Cells for Non-exudative Age-related macular degeneration (AMD)

美国国立卫生研究院资助的再生医学创新催化剂将： ·提供来源干细胞系和正在开发的干细胞衍生产品的深入和独立的特征， ·提供一个共享和分析临床试验(如果适用)和细胞产品特性数据的平台，从而潜在地使干细胞衍生产品属性与临床结果相关联；以及 ·为提高我们对临床结果的理解，改进生产方法，并为未来的RM产品开发奠定基础。 重要的是，RMIC将促进透明度，并最终可能有助于临床级别干细胞衍生产品的重复性和标准化。

The NIH-funded Regenerative Medicine Innovation Catalyst will: • Provide in-depth and independent characterization of the source stem cell line and stem cell-derived products being developed, • Provide a platform for sharing and analysis of clinical trial (if applicable) and cell product characterization data, thereby potentially enabling correlation of stem cell-derived product attributes with clinical outcomes, and • Create a foundation for enhancing our understanding of clinical outcomes, refining production methods, and informing future RM product development. Importantly, the RMIC will promote transparency and ultimately may contribute to reproducibility and standardization of clinical grade stem cell-derived products.